Senior Director Program Management at Vor Bio

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Highly motivated and experienced in program management
Ability to provide leadership across cross-functional teams
Experience in strategic and operational management of late-stage clinical programs in autoimmune diseases
Expertise in overseeing Phase 3 clinical trials, regulatory interactions, and preparation for potential product launch
Capability to align scientific, clinical, regulatory, and commercial strategies in a fast-paced, small biotech environment

Responsibilities

Lead the overall strategy and execution of a global Phase 3 clinical program in autoimmune diseases
Lead effective Program Team meetings and present program strategy to various audiences
Be accountable for the cross-functional execution of one or more program strategy plans, independent of indication or asset
Manage program timeline, cost, quality, and risk mitigation as well as timely escalation where needed
Act as a leader in the clinical development organization to help build cross-portfolio capabilities, recognize consistent challenges, innovate solutions, share best practices, and coach more junior staff
Evaluate new assets, determining time to approval, risks, budget, and overall development plan
Manage the effective operations of Vor Bio cross-functional program teams, focused on the development of one or more disease area programs
Proactively coordinate risk management and ensure contingency and/or risk mitigation plans are developed
Partner with Clinical Operations, Medical, Regulatory, and Biostatistics teams to ensure Phase 3 trial execution meets quality, compliance, and regulatory standards
Support preparation and submission of regulatory documents (NDA/BLA, briefing books, responses to regulatory queries)
Oversee interactions with the FDA, EMA, and other global regulatory agencies
Lead cross-functional core teams (Clinical, Regulatory, CMC, Commercial, Medical Affairs) to ensure integrated program planning and decision-making
Partner with the Program Lead and management to drive development of the Program Strategy Plan, adding value by deriving insights from cross-functional discussions and summarizing those insights in a plan that can be easily communicated and implemented across the enterprise
Facilitate effective business decisions by ensuring integration of key cross-functional input and robust analysis of scenarios, ensuring all decisions are assessed as to their impacts and communicated to stakeholders in a transparent and timely manner
Provide clear communication of program progress, risks, and mitigation strategies to executives

Skills

Program Management

Phase 3 Clinical Trials

Cross-Functional Team Leadership

Regulatory Interactions

Product Launch Preparation

Strategic Planning

Autoimmune Diseases

Clinical Development

Vor Bio

Develops targeted therapies for blood cancers

About Vor Bio

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from competitors is their strong emphasis on research and development, investing significantly in scientific research to create a proprietary platform and pipeline of therapies. They generate revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval. The company's mission is to transform the treatment landscape for blood cancers by providing innovative therapies that prioritize patient safety and efficacy.

Cambridge, MassachusettsHeadquarters

2015Year Founded

$147.9MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Risks

Significant YTD price decline of -62.76% may affect investor confidence.

Key clinical trial data updates are not expected until 2025, causing uncertainty.

Increased competition from companies like Editas Medicine poses potential conflicts.

Differentiation

Vor Bio focuses on protecting healthy cells while targeting cancerous ones.

The company specializes in innovative treatments for blood cancers like AML.

Vor Bio's approach aligns with the rise of personalized medicine.

Upsides

Recent $55.6M funding supports clinical trials and extends cash runway to 2025.

FDA's acceptance of gene therapies may ease approval for Vor Bio's treatments.

Advancements in CRISPR technology enhance precision of Vor Bio's gene editing.

Land your dream remote job 3x faster with AI

Try Jobo Free